Getting Cancer Cells Growing in a Dish
Tissue culture for cancer cells is a set of routine lab techniques used to maintain and study malignant cells outside the body. The basic workflow involves thawing or acquiring cells, placing them in a nutrient medium, incubating them under controlled conditions, passaging them when they reach confluence, and freezing aliquots for later use. People sometimes try to skip steps or cut corners on sterility, and the cultures pay for it quickly. The core process breaks down into a handful of operations that happen in a specific sequence. You start with a culture vessel, usually a T-flask or a multiwell plate, coated or uncoated depending on the cell type. The medium is the most critical variable here. Most commonly used cancer cell lines grow in DMEM or RPMI-1640, supplemented with 10% fetal bovine serum, penicillin-streptomycin, and sometimes non-essential amino acids. The exact formulation depends on the cell line, and you should always check the original publication or the supplier's technical sheet before making assumptions. Once the cells are in the vessel, they need 37 degrees Celsius, 5% CO2, and roughly 95% humidity in an incubator. The CO2 level matters because most media use sodium bicarbonate as a pH buffer, and the bicarbonate system only equilibrates properly at a specific CO2 concentration. If your incubator's CO2 sensor is drifting and you don't notice it, the medium will turn purple or yellow over a few days and the cells will detach or die. This happens more often than people admit.
When the cells reach about 80 to 90% confluence, you need to passage them. For adherent lines, this means aspirating the old medium, washing with PBS, adding a small volume of trypsin-EDTA, waiting two to five minutes at 37 degrees, neutralizing with serum-containing medium, and splitting the suspension into new vessels at a defined ratio. Suspension lines like many leukemia cell lines just need dilution into fresh medium. The split ratio varies by line. Some double every 24 hours, others take three days. A498 renal carcinoma, for example, passages roughly 1:10 every three days, while MDA-MB-231 breast cancer cells might go 1:6 daily under optimal conditions. Cryopreservation follows a standard protocol: harvest cells, resuspend in freezing medium containing 10% DMSO and 90% FBS at a density of roughly one million cells per milliliter, place the vial in a Mr. Frosty or similar controlled-rate container, and move it to minus 80 degrees overnight before transferring to liquid nitrogen. The DMSO needs to be fresh and sterile. Old DMSO degrades and becomes cytotoxic, and you will get poor post-thaw recovery without even realizing why at first. I once spent three weeks trying to figure out why a freshly ordered batch of MCF7 cells was growing abnormally slowly. The morphology looked fine, the medium looked fine, the CO2 was holding steady. It turned out the shipment had sat on a delivery truck for sixteen hours before reaching the lab, and although the liquid nitrogen dewar was intact, the internal temperature had risen enough to cause partial thawing during transit. The cells weren't dead, but their doubling time had shifted from about 24 hours to over 60. I discarded the batch, reordered with dry ice padding and a temperature logger, and made sure the receiving lab had a cold chain verification step. That process took me about 45 minutes and saved months of wasted experiments.
One thing that catches people off guard is that cancer cells are not a monolith. A solid tumor biopsy contains epithelial cancer cells, fibroblasts, immune cells, endothelial cells, and extracellular matrix. When you try to establish a primary culture from a fresh surgical specimen, the fibroblasts usually outgrow everything else within a week. The cancer cells may be present but starved for space and nutrients. The workaround is either to use selection media, rely on differential adhesion properties, or process the tissue with enzyme digestion and density gradient separation before plating. Even then, primary tumor cultures fail at a rate of roughly 60 to 80 percent depending on the tumor type and how quickly the sample reaches the lab after resection. Established cell lines are far more reliable for routine work, but they do not accurately model the heterogeneity of the original tumor. Another practical detail that people frequently get wrong is mycoplasma testing. Contamination with mycoplasma bacteria does not change the clarity of the medium. You cannot see it under a standard light microscope unless you use a fluorescent DNA stain. Mycoplasma silently alters gene expression, changes metabolism, slows growth rates, and skews drug sensitivity results. I recommend running a PCR-based detection kit every month on every active line, and freezing a clean early-passage stock before any long-term project begins. The test itself takes about 90 minutes and costs roughly fifteen dollars per sample. Authentication is equally important. The ATCC estimates that around 18 to 30 percent of cell lines in active use are misidentified or cross-contaminated with another line. HeLa cells, in particular, have contaminated thousands of other cultures over the decades. Short tandem repeat profiling is the standard method, and it costs between 80 and 200 dollars per sample depending on the laboratory. Running STR profiling on any new line before you commit significant resources to it is not optional if you plan to publish or share data.
Get the Full Details
There are real limitations to this approach. Cancer cell lines adapted to two-dimensional plastic culture lose many of the features that matter in vivo, including cell-cell junctions, polarization, and interaction with the stromal microenvironment. Drug response data from monolayer cultures does not reliably predict clinical outcomes. Organoid cultures and patient-derived xenografts address some of these gaps, but they introduce their own complexity, longer timelines, and higher costs. No single model captures everything. If you are starting out, keep the first few passages simple. Use well-characterized lines like HeLa, MCF7, or A549 until you have a consistent routine. Track passage number carefully, because phenotype drifts significantly after passage 25 to 30 in many lines. Maintain a notebook or electronic log with dates, split ratios, medium lots, and any anomalies you observe. Small details like which batch of FBS you are using will matter more than you expect when something goes wrong and you need to troubleshoot it retroactively.
